BY002 for relapsed or refractory acute leukemia with KMT2A rearrangements or NPM1 mutations

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This single-center, open-label phase 1 trial uses a 3+3 dose-escalation design with an expansion cohort to define the recommended phase 2 dose of BY002. Eligible adults with relapsed or refractory AML, ALL, or MPAL (excluding APL) who harbor KMT2A rearrangements or NPM1 mutations will receive oral BY002 in 28-day cycles until disease progression, unacceptable toxicity, hematopoietic stem cell transplant, withdrawal, or death. Primary endpoints are dose-limiting toxicities, serious adverse events, and determination of the maximum tolerated dose and RP2D, and secondary endpoints include pharmacokinetics, comprehensive safety monitoring, and preliminary anti-leukemia activity. Safety evaluations include adverse event reporting, laboratory tests, vital signs, and ECGs performed at scheduled visits.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age ≥16 years.
* Confirmed diagnosis of AML, ALL, or MPAL per WHO 2022 criteria.
* Relapsed or refractory disease after ≥1 prior therapy.
* Presence of KMT2A rearrangement or NPM1 mutation (preferred, but not exclusive).
* ECOG performance status 0-2.
* Adequate organ function:
* ANC ≥1.0 × 10⁹/L (unless cytopenia due to leukemia)
* Platelets ≥50 × 10⁹/L (unless due to leukemia)
* ALT/AST ≤2.5 × ULN, bilirubin ≤1.5 × ULN
* Creatinine clearance ≥50 mL/min
* Negative pregnancy test for women of childbearing potential.
* Willing to use effective contraception during study and 90 days after last dose.
* Signed informed consent.

Exclusion Criteria:

* Active central nervous system (CNS) leukemia. (Prior CNS involvement allowed if treated and controlled; CNS prophylaxis permitted.)
* History of significant liver disease, including viral hepatitis or cirrhosis:
* HBsAg positive must have negative HBV DNA.
* HCV antibody positive must have negative HCV RNA.
* Known HIV infection.
* Pregnant or breastfeeding women.
* Significant cardiac disease:
* Congenital long QT syndrome or QTcF \>450 msec.
* Acute myocardial infarction, unstable angina, or coronary artery bypass within 6 months.
* Congestive heart failure ≥ NYHA class II.
* History of another malignancy within 5 years, except adequately treated basal cell carcinoma of the skin, in-situ breast cancer, or in-situ cervical cancer.
* Autologous HSCT or CAR-T therapy within 60 days, or unresolved toxicities from ASCT/CAR-T.
* Allogeneic HSCT within 100 days, or active GVHD, or requiring ongoing immunosuppressive therapy.
* Anti-leukemia therapy within 2 weeks before study entry (hydroxyurea permitted).
* Prior investigational drug use: \<2 weeks or \<5 half-lives for small molecules; \<4 weeks or \<5 half-lives for biologics (whichever is shorter).
* Unresolved toxicities \> grade 1 from prior anti-leukemia therapy (except alopecia).
* Uncontrolled active infection:
* Mild infections manageable with oral/topical treatment are allowed.
* Serious infections requiring hospitalization/IV antibiotics within 14 days excluded, unless resolved.
* Febrile neutropenia without infection evidence may be eligible if afebrile \>72 h without antipyretics.
* Active tuberculosis excluded.
* Conditions impairing oral intake or absorption (e.g., swallowing difficulty, short bowel syndrome, gastroparesis).
* Known severe allergy to Menin inhibitors or any component of BY002.
* Investigator judges poor compliance or inability to complete study.
* Any other serious disease, abnormality, or condition that may increase risk, interfere with study drug, confound results, or expected survival ≤6 months.

Where it's running

• The First Affiliated Hospital of Soochow University
  Suzhou, Jiangsu, China Recruiting

Study contacts

• Principal investigator: Suning Chen, MD, PhD — The First Affiliated Hospital of Soochow University
• Study coordinator: Jing Lu Doctor, MD, PhD
• Email: gloriajlu@163.com
• Phone: 86+0512-67781137

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Menin inhibitors in pediatric relapsed or refractory acute leukemia

  This study looks at kids with relapsed or treatment-resistant acute leukemia who have specific genetic changes and are treated with menin inhibitors to see how they fare.

  Recruiting University Hospital, Strasbourg, France · Strasbourg · NCT07898436

• Artistic and movement activities to help anxiety in kids with ALL

  Kids aged 8–13 with acute lymphoblastic leukemia test whether a 16-session art and movement program can reduce anxiety compared with standard care.

  Recruiting Phase 3 Children's Cancer Hospital Egypt 57357 · Cairo, Cairo Governorate · NCT07878065

• Strength Training for Kids with Acute Lymphoblastic Leukemia and Lymphoblastic L lymphoma

  Researchers are testing a structured strength-training program for children and teens recently diagnosed with ALL or lymphoblastic lymphoma to see if it helps with weight gain and physical function during treatment.

  Recruiting UNC Lineberger Comprehensive Cancer Center · Chapel Hill, North Carolina · NCT07634653

• QUAIL-100 in kids and young adults after stem cell transplant with high-risk blood cancers

  This study tests QUAIL-100 in pediatric and young adult patients who have high-risk acute leukemia or myelodysplastic syndrome and have already received a partially matched stem cell transplant.

  Recruiting Phase 1 Laguna Biotherapeutics, Inc. · Palo Alto, California · NCT07573111

• Thiotepa-based Conditioning With Reduced Post-Transplant Cyclophosphamide for Allogeneic Stem Cell Transplant in High-Risk Blood C cancers

  This phase 1 trial tests a Thiotepa, Busulfan, and Fludarabine conditioning regimen with de-escalated post-transplant cyclophosphamide to see if it can improve outcomes after allogeneic stem cell transplantation for high-risk blood cancers.

  Recruiting Phase 1 University of Pittsburgh · Pittsburgh, Pennsylvania · NCT07565220

• Menin inhibitor maintenance after allogeneic stem cell transplant

  This project will try menin inhibitor maintenance to see if it helps people with acute leukemia after allogeneic stem cell transplant who have KMT2A or related gene changes.

  Recruiting The First Affiliated Hospital of Soochow University · Suzhou, Jiangsu · NCT07559695

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.